Ardent Health, Inc. (ARDT) Q4 2025 Earnings Call Transcript
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.81 per share a year ago.
We believe Ardent Health (ARDT) stock is worth considering: It is growing, generating cash, and is priced at a notable valuation discount. Companies of this caliber can utilize cash to drive further revenue growth, or simply reward their shareholders through dividends or buybacks.
We believe Ardent Health (ARDT) stock deserves attention: It is growing, generating cash, and is priced significantly below its valuation. Companies like this can utilize cash to drive further revenue growth or distribute it to their shareholders via dividends or buybacks.
DIOD, ARDT and FFIV have been added to the Zacks Rank #5 (Strong Sell) List on November 18, 2025.
Ardent Health, Inc. ( ARDT ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants David Styblo - Senior Vice President of Investor Relations Martin Bonick - President, CEO & Director Alfred Lumsdaine - Chief Financial Officer Conference Call Participants Jason Cassorla - Guggenheim Securities, LLC, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Kevin Fischbeck - BofA Securities, Research Division Zach Haggerty Raj Kumar - Stephens Inc., Research Division Craig Hettenbach - Morgan Stanley, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.19 per share a year ago.
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.35 per share a year ago.
Ardent Health, Inc. (ARDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardent Health faces significant legislative risks, due to Medicaid and Medicare cuts, causing uncertainty and a recent downgrade, but much of this is priced in. Despite headwinds, Ardent Health demonstrates strong revenue and profitability growth, low leverage, and trades at compellingly cheap valuations, versus peers. Management projects continued growth for 2025, with revenue and EBITDA expected to rise, supported by higher-margin service expansions and acquisitions.
The mean of analysts' price targets for Ardent Health Partners, Inc. (ARDT) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ardent Health Partners, Inc. (NYSE:ARDT ) Q1 2025 Earnings Conference Call May 7, 2025 10:00 AM ET Company Participants David Styblo - Senior Vice President of Investor Relations Marty Bonick - President and Chief Executive Officer Alfred Lumsdaine - Chief Financial Officer Conference Call Participants Whit Mayo - Leerink Partners Ann Hynes - Mizuho Craig Hettenbach - Morgan Stanley Ben Hendrix - RBC Capital Markets Joanna Gajuk - Bank of America Matthew Gillmor - KeyBanc Benjamin Rossi - JPMorgan Operator Ladies and gentlemen, thank you for standing by, and welcome to the Ardent Health Partners First Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded.